{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-044135","form_type":"8-K","ticker":"LENZ","cik":"0001815776","company_name":"LENZ Therapeutics, Inc.","filed_at":"2023-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.386044+00:00","generated_at":"2026-06-11T04:55:53.420291+00:00","sec_items":["8.01","2.05","5.02"],"event_type":"other_material","sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Graphite Bio appoints new CEO, cuts 70% of workforce","bullets":["Kimberlee C. Drapkin appointed President & CEO, effective Aug 21, 2023; base salary $550,000.","Board approved a restructuring plan reducing workforce by approximately 70%.","Estimated severance and related costs of ~$1.6 million, recorded primarily in Q3 2023.","Former CEO Josh Lehrer separated; entitled to Tier 1 severance and retention benefits.","Company continues exploring strategic alternatives as part of corporate restructuring."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-044135","json":"https://secwatch.observer/filing/0000950170-23-044135.json","markdown":"https://secwatch.observer/filing/0000950170-23-044135.md","text":"https://secwatch.observer/filing/0000950170-23-044135.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023044135/0000950170-23-044135-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023044135/grph-20230818.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T04:55:53.420291+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e42c838d64de86de9a44854519860d077f7a2c5c","claim":"LENZ Therapeutics, Inc. announced a restructuring with charges of approximately $1.6 million (approximately 70%).","evidence_excerpt":"alternatives. Under the Plan, the Company is reducing its workforce by approximately 70%. The Company expects to incur estimated severance and related costs of approximately $1.6 million, which will be recorded primarily in the third quarter of 2023. As the Plan is implemented, the Company’s management will re-evaluate the estimated costs and expenses set forth","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1815776/000095017023044135/0000950170-23-044135-index.htm","confidence":0.9,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $1.6 million"},{"label":"Headcount","value":"approximately 70%"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}